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TMEM70atients with nuclear genetic defects of mitochondrial ATP synthase have been
identiﬁed in recent years. They are characterized by early onset, lactic acidosis, 3-methylglutaconic aciduria,
hypertrophic cardiomyopathy and encephalopathy and most cases have a fatal outcome. Patient tissues show
isolated defect of the ATP synthase complex and its content decreases to ≥30% of normal due to altered
enzyme biosynthesis and assembly. Gene mapping and complementation studies have identiﬁed mutations
in TMEM70 gene encoding a 30kD mitochondrial protein of unknown function as the cause of the disease. An
altered synthesis of this new ancillary factor in ATP synthase biogenesis was found in most of the known
patients with decreased ATP synthase content. As revealed by phylogenetic analysis, TMEM70 is speciﬁc for
higher eukaryotes.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionWithin the last few years, a growing number of human mitochon-
drial diseases, due to nuclear genetic defects of mitochondrial
oxidative phosphorylation (OXPHOS) complexes, have been diag-
nosed and an increasing number of affected genes have been
identiﬁed. They code for structural subunits or helper proteins that
are essential for assembly of the OXPHOS complex, subunit processing
or biosynthesis of speciﬁc cofactors [1].
Up to now, nuclear genetic defects could be found in isolated
disorders of all mitochondrial respiratory chain complexes but the
number of affected genes clearly does not correspond to the structural
complexity of the individual OXPHOS complexes or with numerous,
complex-speciﬁc ancillary proteins essential for their biogenesis. This
holds true particularly for complex I, NADH dehydrogenase, which is
not present in S. cerevisiae, that has provided the most signiﬁcant
genetic “background information” for mammalian mitochondrial ge-
nomics, but is also true for complex IV — cytochrome c oxidase, and
complex V — FOF1 ATP synthase. In cytochrome c oxidase (COX), 19
ancillary factors have been described in yeast, 16 of which have their
homologues in humans [2]. Out of these, SURF1, SCO1, SCO2, COX10
and COX15 have been found to be responsible for COX deﬁciency,
either because of mutation in the factor or its absence [3]. Although
the COX complex contains 10 nuclear encoded subunits, only one ofcatalytic part of ATP synthase,
tochrome c oxidase; mtDNA,
; ROS, reactive oxygen species
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ll rights reserved.them, COX6B1, has been recently found to be responsible for COX
dysfunction leading to human disease [4]. Even less is known about
the pathogenesis of ATP synthase, where only nuclear gene for the
F1-assembly factor ATP12 has so far been associated with an isolated
enzyme deﬁciency [5].
In some cases, the search for the genes responsible for dysfunction
of the mitochondrial respiratory chain complex has led to the
discovery of a new, previously unknown mitochondrial protein. For
example, the LRPPRC (leucine-rich pentatricopeptide repeat cassette)
gene, speciﬁc for higher eukaryotes and responsible for the Leigh
syndrome French Canadian (LSFC) variant of COX deﬁciency, was
identiﬁed by integrative genomics [6]. However, a large number of
OXPHOS diseases still remain unexplained and a better knowledge of
the mammalian mitochondrial proteome is of key importance for
identiﬁcation of disease-causing genes. Some 1451 human mitochon-
drial proteins encoded by 1080 genes have been predicted by recent
studies based on integrative genomicswhich combined 8 independent
approaches parameters using a naive Bayes classiﬁer implemented
with a Maestro computer program [7]. Most of them were further
validated by mass spectrometry of puriﬁed mitochondrial proteins
fromdifferent tissues andbyGFP tagging [8]. These powerful strategies
predicted a number of new mammalian mitochondrial proteins
including 19 assembly factors for mitochondrial complex I and directly
enabled identiﬁcation of candidates for novel mitochondrial disease-
causing genes, as for example MPV17 in the case of mtDNA depletion
syndrome [9] or C8orf38 in infantile lethal complex I deﬁciency [8].
2. ATP synthase biogenesis
Mammalian FOF1-ATP synthase is a heterooligomeric mitochon-
drial complex made up of 16 different subunits [10]. The catalytic F1
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attached IF1 inhibitor protein; F1 is connected by two stalks to the
membrane-embedded FO portionwhich functions as a proton channel
and consists of an additional ten subunits, a, b c, d, e, f, g, OSCP, A6L,
and F6. Subunits a and A6L (subunits 6 and 8) are mtDNA encoded; all
other subunits are coded for by the nuclear DNA.
The current concept of ATP synthase biogenesis stems from
evolutionary divergent models such as bacterial, yeast and mamma-
lian cells. Indeed, yeast served as a momentous model for the
elucidation of ATP synthase biogenesis and assembly in eukaryotes,
however, several basic differences exist between the yeast and the
mammalian enzyme. In addition to subunits 6 and 8, the yeast
mitochondrial genome encodes subunit 9 (subunit c); the yeast
subunit 6 is synthesized in a precursor form and the intron–exon
organization of the yeast mtDNA leaves an additional space for trans-
criptional regulation.
Eukaryotic ATP synthase is formed stepwise and enzyme
assembly begins with formation of the F1 catalytic part which then
associates with subunits c and the other FO subunits [11]. The two
mtDNA encoded subunits, 6 and 8, appear to be added, at least in the
mammalian enzyme, during the last stage of enzyme assembly
[12,13].
The biogenesis of eukaryotic ATP synthase is dependent on the
mutual action of several helper proteins, which serve chaperone-type
functions, speciﬁc to the assembly of ATP synthase. Moreover, there
are other proteins that govern the expression of ATP synthase genes
at different levels (Table 1). This process is well known in yeast [11,14–
16]) which requires several factors involved in F1 assembly (ATP11,
ATP12, FMC1) and FO assembly (ATP10, ATP23). In addition other
factors are involved in mRNA stability, translation and processing of
mtDNA encoded subunits (NCA1-3, NAM1, AEP1-3 ATP22, ATP25)
(Table 1). Inmammalianmitochondria, only functional homologues of
ATP11 and ATP12, have been found [11,17,18], i.e. the F1 chaperons
interacting with subunits β and α. Both are absolutely essential for
assembly of the functional α3β3 heterooligomer. Due to the above
mentioned differences in organization and expression of the mito-
chondrial genome in yeast, all other ancillary factors described in S.
cerevisiae are missing in higher eukaryotes. The only exception might
be the recently identiﬁed ATP23 gene [14,19] which encodes a 32 kDA
metalloprotease of the inner mitochondrial membrane, having
chaperone activity in the intermembrane space. ATP23 has two
functions in yeast, processing of the subunit 6 precursor and
association of the subunit 6 with subunit 9 oligomer. There exists a
mammalian ortholog of ATP23 which contains a HEXXH motif of the
protease active site, but its function is unknown, also because the
mammalian subunit a lacks the precursor. On the one hand it is thus
understandable why most of the known yeast auxiliary proteins for
ATP synthase biogenesis are absent in mammals, on the other handTable 1
Ancillary proteins involved in the biogenesis of yeast and mammalian ATP synthase
(based on [11,14–16,19,36])
Genes Yeast Mammals Target Function
ATP11 + + F1 subunit β Chaperone
ATP12 + + F1 subunit α Chaperone
FMC1 + − Atp12p/F1 subunit
α
Co-chaperone
TMEM70 − + ? ?
NAM1 + − Subunit 6 and 8 mRNA processing
AEP3, NCA2, NCA3 + − Subunit 6 and 8 mRNA stability/
translation
ATP22 + − Subunit 6 Translation
ATP10 + − Subunit 6 Chaperone
ATP23 + ? Subunit 6 Processing/assembly
NCA1, ATP25 + − Subunit 9 mRNA stability
AEP1, AEP2/ATP13 + − Subunit 9 Translationthemultisubunit heterooligomer structure of ATP synthase complex is
equally complicated in lower and higher eukaryotes, and it is possible
that additional mammalian assembly factors may exist.
3. Nuclear genetic defects of ATP synthase biogenesis
ATP synthase is the key enzyme in ATP production in mammalian
cells and its dysfunction represents a serious problem in energy
supply for vital functions. Mitochondrial diseases due to isolated
defects of ATP synthase belong to the most severe metabolic disorders
and typically affect newborns and small children. This holds true for
mtDNA defects as well as for nuclear genetic defects which represent
distinct types of mitochondrial diseases, from both a biochemical and
a clinical point of view.
Maternally transmitted ATP synthase dysfunction can be caused by
mtDNA heteroplasmic missense mutations in ATP6 [20–22], altered
splicing of ATP6-COX3 mRNA [23,24], or a premature stop codon in
ATP8 [25] gene. The enzyme subunits are usually present in near-
normal amounts but in many cases BlueNative electrophoresis has
revealed a reduced content of the assembled ATP synthase complex
and accumulation of incomplete FOF1 subcomplexes. ATP synthase is
affected by altered protonophoric function of the membrane FO sector
and intra-enzyme coupling of H+-transport and ATP synthase
catalytic activity [26]. The utilization of an electrochemical proton
gradient for ATP synthesis is highly depressed and, as a result, the cell
suffers from energetic deprivation but also from increased ROS
synthesis, as demonstrated in 8993T/G homoplasmic cybrids [27].
Patients with the ATP6 mutations mostly show CNS involvement and
they present with neuropathy, ataxia, and retinitis pigmentosa
(NARP), maternally inherited Leigh syndrome (MILS), or bilateral
striatal necrosis, while hypertrophic cardiomyopathy has been found
in the case of ATP8 mutation [25].
A completely different type of mitochondrial disorders are isolated
defects of ATP synthase of nuclear genetic origin (OMIM 604273), that
are autosomal recessive [28]. They are characterized by a severely
decreased content of an otherwise structurally and functionally
normal enzyme resulting from impaired biosynthesis of the ATP
synthase complex, which appears to be associated with the initial
stage of enzyme biogenesis, the assembly of the F1 catalytic part [28].
Patient's cells have diminished ability to synthesize ATP and due to the
altered discharge of the mitochondrial proton gradient, mitochondria
of ATP synthase-deﬁcient patients show elevated level of membrane
potential which, in turn, activates mitochondrial ROS production
[29,30].
Within the last several years increasing numbers of patients with
nuclear genetic ATP synthase defects has been found; mostly
presenting with early onset lactic acidosis, cardiomyopathy, variable
CNS involvement and 3-methylglutaconic aciduria [13,31]. In 2004 the
search for the disease-causing gene(s) resulted in the identiﬁcation of
a homozygous missense mutation in the third exon of the ATP12 gene
which replaced tryptophan 94 with arginine. The mutationwas found
in a patient with severe encephalopathy and it was conﬁrmed that the
primary defect was in the assembly of the F1 catalytic part of ATP
synthase, due to dysfunction of one of the F1 speciﬁc assembly factors
[5]. Nevertheless, this case turned out to be rather atypical and neither
the ATP11, nor the ATP12 genes have been mutated in number of other
diagnosed cases [31], inwhich also nomutations could be found in the
ATP synthase subunit genes.
4. TMEM 70 — novel factor in ATP synthase biogenesis
Further attempts to uncover the pathogenic mechanism have been
made to test whether the ATP synthase deﬁciency could be caused by
the lack of ATP11 or ATP12 assembly factors or by limited availability
of one or more structural subunits, in a similar fashion as low
expression of subunit c downregulates ATP synthase in thermogenic
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proﬁling has been performed in 13 cases with ATP synthase deﬁciency
using both tailored and commercial oligonucleotide DNA microarrays.
However, the results did not show any pronounced downregulation of
ATP synthase subunits or other known ATP synthase-related genes
[35]. Therefore, to identify the affected disease causing gene(s),
linkage analysis and homozygosity mapping of selected index patients
from several unrelated families was performed using Affymetrix
GeneChip Mapping 250K arrays. The observed homozygosity proﬁles
were intersected with whole genome expression proﬁles determined
in patient ﬁbroblast (Agilent 44kArray). As a result, gene TMEM70 on
chromosome 8 was identiﬁed as a highly probable candidate, and
subsequently shown to be mutated [36].
Pathogenicity of TMEM70 mutations was conﬁrmed in comple-
mentation experiments where ﬁbroblasts from ATP synthase-
deﬁcient patients were transfected with wild type TMEM70 cDNA
cloned into the pEF-DEST51 expression vector [36] (Fig. 1A). As a
result, the cellular content of ATP synthase subunits as well as the
content of intact ATP synthase complex were restored (Fig. 1B) thus
demonstrating that the absence-dysfunction of TMEM70 proteins was
the primary cause of the disease. Complementation studies further
showed that wtTMEM70 also restored oligomycin sensitive ATPase
activity, ADP-stimulated respiration and mitochondrial ATP synthesis.
Consequently, the mitochondria in wtTMEM70-complemented ﬁbro-
blasts also recovered the ADP-induced decrease in membrane
potential in substrate-supplemented, digitonin-permeabilised ﬁbro-
blasts [36].
The TMEM70 gene consists of three exons and encodes a 260 amino
acid protein of unknown function. In all genotyped cases, a substitution
(c.317–2ANG) was found, located in the splicing site of intron 2, which
leads to aberrant splicing and loss of the TMEM70 transcript, thus
preventing synthesis of the protein. Further analysis of known cases
with isolated ATP synthase deﬁciency revealed the presence of a homo-
zygous c.317-2ANG mutation in 23 cases and one compound hetero-
zygote patient with the second TMEM70 mutation (c.118_119insGT)
[36]. Out of all the cases analyzed, there was only one case where
TMEM70, ATP11 and ATP12 were all found to be unmutated, indicating
that an additional gene must be involved in ATP synthase deﬁciency.
Practically all patients with the TMEM70 mutation were of Roma/
Gypsy origin, but consanguinity has only been reported in a few cases.
Estimation of consanguinity and/or degree of relationship between
individual families and patients, from genotyping data available from
Czech and Slovak families, suggests that the parents from the individualFig. 1. Complementation of ATP synthase deﬁcient ﬁbroblast with wtTMEM70. (A) TMEM70
transfected with TMEM70-pEF-DEST51 (P+TMEM70), (B) BlueNative-PAGE analysis of laury
immunodetection was performed with monoclonal anti-F1 α subunit antibody (1 μg/ml, MS
Imager (LiCor Biosciences). (C) Relative content of fully assembled FOF1 ATP synthase comple
B using Aida 2.11 Image Analyzer software (Raytest).families may be relatives of the 3rd–6th generation. Based on this
information and considering the fact that we analyzed the majority of
patients known and available to us, it appears that isolated ATP synthase
deﬁciency is a defect occurring frequently in theRomapopulation due to
the founder allele effect. This fact however does not exclude the
possibility that in the other populations the same defect may results
from other mutations in the TMEM70 gene (as P27 in ref [36]).
5. TMEM 70 function and evolution
TMEM70was identiﬁed by integrative genomics as one of the novel
genes encoding mitochondrial proteins and GFP-tagged TMEM70 has
been shown to be localized in mitochondria [7]. Although its exact
function is not known at present, it is clear that TMEM70 represents a
novel type of ancillary factor involved in the biogenesis of ATP
synthase. Assuming that TMEM70 mutations completely inhibit
production of the TMEM70 protein, this factor may not be absolutely
essential for ATP synthase biosynthesis, as a small amount of ATP
synthase is always present in affected tissues [28], similarly to the COX
deﬁciency due to the absence of the SURF1 assembly factor [37],
where also residual amounts of the normal COX complex are found.
BlueNative and two-dimensional electrophoretic analysis of ﬁbro-
blasts and tissues from TMEM70 patients revealed the presence of
traces of free F1 ATPase, in addition to small amounts of full size ATP
synthase complexes, but no larger FOF1 subassemblies [28]. Interes-
tingly, in patient ﬁbroblasts after complementation with wtTMEM70,
the restoration of the ATP synthase complex was associated with the
disappearance of unassembled F1 (Fig. 1B, C), indicating that TMEM70
may be involved in the assembly of F1 or in F1 interactionwith some of
the FO subunits.
TMEM70 protein contains a conserved DUF1301 domain and two
putative transmembrane regions indicating that TMEM70 can be a
membrane-associated protein. Using phylogenetic analysis, we found
TMEM70 homologues in genomes of multicellular eukaryotes and
plants, but surprisingly not in yeast or fungi [36]. The only single-cell
organism exception was the choanoﬂagellate protozoan Monosiga
brevicollis, but the degree of homology was very weak.
6. Conclusions
There are two nuclear genes, which when mutated cause isolated
deﬁciencyof humanATP synthase. Bothof themcode for helperproteins
involved in enzyme biogenesis.While the ﬁrst, the rarely mutated F1α-cDNA analysis in ﬁbroblasts from control (C), patient (P) and patients' ﬁbroblasts stably
l maltoside-solubilised mitochondria isolated from ﬁbroblasts of C, P and P+TMEM70,
502, MitoSciences) and IRDye®-labeled secondary antibodies using an Odyssey Infrared
x (FOF1) and of F1-subassembly (⁎F1) in C, P and P+TMEM70, datawere quantiﬁed from
532 J. Houštěk et al. / Biochimica et Biophysica Acta 1787 (2009) 529–532speciﬁc ATP12 is an essential eukaryotic assembly factor, the second
factor, TMEM70, is only present in higher eukaryotes and it appears to be
responsible for a vast majority of cases of ATP synthase deﬁciency of
nuclear genetic origin, at least in the Roma population.
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